A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130
Background: T900607 is a novel tubulin active agent which disrupts microtubule polymerization by a unique mechanism of action. This phase I trial was conducted to determine the maximum tolerated dose, recommended phase II dose, pharmacokinetic properties and toxicities of this agent. Patients and methods: Patients with advanced and/or metastatic solid malignancies were enrolled, for an open dose escalation of T900607 administered intravenously over 30 minutes every 21-days. Results: Thirty patients were enrolled on 7 dose levels ranging from 15 to 270 mg/m2. No DLTs were seen until 270 mg/m2, the sixth dose level, with 1 patient experiencing Grade 3 thrombocytopenia, 1 grade 4 troponin increase and 1 grade 5 myocardial infarction in an expanded cohort of 6 patients. The dose was decreased to 180 mg/m2 with increased cardiac monitoring and at this dose 3/4 patients experienced cardiac toxicity. Further animal cardiotoxicity studies failed to reveal any cardiac effects and the study was reopened at 130 mg/m2; of 6 enrolled patients, 1 had grade 3 drug related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported in 7/20. Pharmacokinetic analysis showed that AUC and Cmax increased with dose with considerable intrapatient variability, a short half life of < 1 hour, and no apparent dose dependency clearance. Conclusions: The recommended phase II dose for T900607 is 130 mg/m2 given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule.
Keywordsphase I tubulin active agent
Unable to display preview. Download preview PDF.
- 2.Drukman S, Kavallaris M: Microtubule alteration and resistance to tubulin binding agents (Review). Int Jour of Oncol 21: 621–628, 2002Google Scholar
- 5.Lewis SA, Cowen MJ: Tubulin genes, structure, expression and regulators of microtubule proteins. In: Avila J. (ed), CRC Press Inc. TL pp. 37–66, 1999Google Scholar
- 6.Kavallaris M, Kuo DY-S, Burkart CA, Regl DL, Norris MD, Haber M, Horowitz SB: Taxol resistant epithelial ovarian tumors are associated with altered expression of specific β tubulin isotypes. J Clin Inves 100: 1282–1293, 1999Google Scholar
- 8.Investigators Manual for T900607. Tularik Inc. 2000Google Scholar
- 9.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein C, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–16, 2000Google Scholar
- 11.Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Roberson DH, Hille DA, Delucca PT, DiBattisti PM, Demopoulos LA, Weintraub WS, Braunwald E: Ability of minor elevations of troponins I and T to predict benefit for an early invasive strategy in patients with unstable angina and non ST elevation myocardial infarctions; results from randomized trials. JAMA 286: 2405–2412, 2001CrossRefPubMedGoogle Scholar
- 15.Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E: Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.) Cirulation 109(5): 565–570, 2004Google Scholar